SEQUENCE LISTING

<110> Raschke, Eva
Wolffe, Alan P
Case, Casey C

<120> METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN

<130> SABI-006/01US (S12-US1)

<140> 09/844,662
<141> 2001-04-27

<150> 60/200,590
<151> 2000-04-28

<160> 39

<170> PatentIn version 3.2

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: target site 1

<400> 1
ggggaggatc gcggaggctt 20

<210> 2
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sequence upstream of target site 1

<400> 2
ggggaggatc 10

<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: target site 2

<400> 3
gagtgtgtga actgcggggc aa 22

<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 1 F4

<400> 4
Thr Thr Ser Asn Leu Arg Arg
1 5

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 1 F5

<400> 5
Arg Ser Ser Asn Leu Gln Arg
1 5

<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 1 F6

<400> 6
Arg Ser Asp His Leu Ser Arg
1 5

<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F1

<400> 7
Gln Ser Ser Asp Leu Gln Arg
1 5

<210> 8
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F2

<400> 8

Arg Ser Ser Asn Leu Gln Arg
1 5

<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F3

<400> 9
Arg Ser Asp Glu Leu Ser Arg
1 5

<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F4

<400> 10
Thr Thr Ser Asn Leu Arg Arg
1 5

<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F5

<400> 11
Arg Ser Ser Asn Leu Gln Arg
1 5

<210> 12
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F6

<400> 12
Arg Ser Asp His Leu Ser Arg
1 5

<210> 13

<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F1

<400> 13
Arg Ser Ala Asp Leu Thr Arg
1 5

<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F2

<400> 14
Arg Ser Asp His Leu Thr Arg
1 5

<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F3

<400> 15
Glu Arg Asp His Leu Arg Thr
1 5

<210> 16
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F4

<400> 16
Arg Lys Asp Ser Leu Val Arg
1 5

<210> 17
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F5

<400> 17
Thr Lys Asp His Leu Ala Ser
1 5

<210> 18
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F6

<400> 18
Arg Ser Asp Asn Leu Thr Arg
1 5

<210> 19
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF forward primer

<400> 19
ctggtagcgg ggaggatcg 19

<210> 20
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF reverse primer

<400> 20
gccacgacct ccgagctac 19

<210> 21
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF probe

<400> 21
ctacccggct gccccaagcc tc 22

<210> 22

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: pGL-VFR
forward primer

<400> 22
caagtgcagg tgccagaaca 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: pGL-VFR
reverse primer

<400> 23
cgggactatg gttgctgact 20

<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAPDH forward
primer

<400> 24
ccttttgcag accacagtcc a 21

<210> 25
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAPDH reverse
primer

<400> 25
gcagggatga tgttctggag a 21

<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAPDH probe

<400> 26

cactgccacc cagaagactg tgg 23

<210> 27
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: target
sequence 3

<400> 27
ggggaggag 9

<210> 28
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sequence complementary
to target sequence 3

<400> 28
ctcctcccc 9

<210> 29
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: zinc finger
recognition helix

<400> 29
Arg Ser Asp Asn Leu Thr Arg
1 5

<210> 30
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: zinc finger
recognition helix

<400> 30
Arg Ser Asp Asn Leu Thr Arg
1 5

<210> 31
<211> 7
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: zinc finger
recognition helix

<400> 31
Arg Ser Asp Ala Leu Thr Lys
1 5

<210> 32

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: ER forward
primer

<400> 32
actggctgct tcccgaatc 19

<210> 33
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: ER reverse
primer

<400> 33
cgagtggctc agtgtgtgaa cta 23

<210> 34
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: ER probe

<400> 34
cgcacaaaca catccacaca ctctctctg 29

<210> 35
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Control
forward primer

<400> 35

ttccgataac gaacgagact ct 22

<210> 36
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Control
reverse primer

<400> 36
tggctgaacg ccacttgtc 19

<210> 37
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Control probe

<400> 37
taactagtta cgcgaccccc gag 23

<210> 38
<211> 10
<212> DNA
<213> Artificial

<220>
<223> binding site for a ZFP

<220>
<221> misc_feature
<222> (1)..(2)
<223> n = any nucleotide

<220>
<221> misc_feature
<222> (3)..(4)
<223> (N,N) = (any nucleotide, any nucleotide) or (G,K)

<220>
<221> misc_feature
<222> (5)..(5)
<223> N = any nucleotide

<220>
<221> misc_feature
<222> (6)..(7)
<223> (N,N) = (any nucleotide, any nucleotide) or (G,K)

<220>

<221> misc_feature
<222> (8)..(8)
<223> N = any nucleotide

<220>
<221> misc_feature
<222> (9)..(10)
<223> (N,N) = (any nucleotide, any nucleotide) or (G,K)

<400> 38
nnnnnnnnnn 10

<210> 39
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: NLS

<400> 39
Pro Lys Lys Lys Arg Lys Val
1 5